NCT05033691View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

NARecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
NSCLCEGFR Gene MutationEGF-R Positive Non-Small Cell Lung CancerNon-small Cell Lung CancerBrain Metastases
Interventions
RADIATION

Stereotactic surgery

At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.

Trial Locations (1)

9112001

RECRUITING

Hadassah Ein Kerem Medical Center, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER

NCT05033691 - A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases | Biotech Hunter | Biotech Hunter